IL196897A - Preparations based on 1- (3-Chloro-5 - {[4- (4-Chloro-Ophen-2-Il) -5- (4-Cyclohexylpiperazine-1-Il) Thiazole-2-Il] Carbamoyl} Pyridine-2-Il ) Carboxylic acid or salts, to increase levels of human platelet - Google Patents

Preparations based on 1- (3-Chloro-5 - {[4- (4-Chloro-Ophen-2-Il) -5- (4-Cyclohexylpiperazine-1-Il) Thiazole-2-Il] Carbamoyl} Pyridine-2-Il ) Carboxylic acid or salts, to increase levels of human platelet

Info

Publication number
IL196897A
IL196897A IL196897A IL19689709A IL196897A IL 196897 A IL196897 A IL 196897A IL 196897 A IL196897 A IL 196897A IL 19689709 A IL19689709 A IL 19689709A IL 196897 A IL196897 A IL 196897A
Authority
IL
Israel
Prior art keywords
cyclohexylpiperazin
piperadine
chlorothiophen
thiazol
carbamoyl
Prior art date
Application number
IL196897A
Other languages
English (en)
Hebrew (he)
Other versions
IL196897A0 (en
Inventor
Robert E Desjardins
Rudolph Lucek
Original Assignee
Akarx Inc
Robert E Desjardins
Rudolph Lucek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarx Inc, Robert E Desjardins, Rudolph Lucek filed Critical Akarx Inc
Publication of IL196897A0 publication Critical patent/IL196897A0/en
Publication of IL196897A publication Critical patent/IL196897A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL196897A 2006-08-08 2009-02-04 Preparations based on 1- (3-Chloro-5 - {[4- (4-Chloro-Ophen-2-Il) -5- (4-Cyclohexylpiperazine-1-Il) Thiazole-2-Il] Carbamoyl} Pyridine-2-Il ) Carboxylic acid or salts, to increase levels of human platelet IL196897A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83633406P 2006-08-08 2006-08-08
PCT/US2007/017860 WO2008021283A2 (en) 2006-08-08 2007-08-08 Compositions and methods for increasing blood platelet levels in humans

Publications (2)

Publication Number Publication Date
IL196897A0 IL196897A0 (en) 2011-08-01
IL196897A true IL196897A (en) 2015-08-31

Family

ID=39082656

Family Applications (4)

Application Number Title Priority Date Filing Date
IL196897A IL196897A (en) 2006-08-08 2009-02-04 Preparations based on 1- (3-Chloro-5 - {[4- (4-Chloro-Ophen-2-Il) -5- (4-Cyclohexylpiperazine-1-Il) Thiazole-2-Il] Carbamoyl} Pyridine-2-Il ) Carboxylic acid or salts, to increase levels of human platelet
IL240322A IL240322A0 (en) 2006-08-08 2015-08-03 Preparations based on 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazio-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl Piperadine-4-carboxylic acid or salts, to increase levels of platelets in human blood
IL240323A IL240323A (en) 2006-08-08 2015-08-03 Preparations based on 1 - (3-chloro-5 - {[4- (4-chloro-phenyl-2-ram) -5- (4-cyclohexylpiperazine-1-ram) thiazole-2-ram] carbamoyl} pyridine-2-ram ) Carboxylic acid or salts, to increase levels of human platelet
IL245911A IL245911A0 (en) 2006-08-08 2016-05-29 Compositions and methods for increasing the level of blood platelets in humans

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL240322A IL240322A0 (en) 2006-08-08 2015-08-03 Preparations based on 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazio-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl Piperadine-4-carboxylic acid or salts, to increase levels of platelets in human blood
IL240323A IL240323A (en) 2006-08-08 2015-08-03 Preparations based on 1 - (3-chloro-5 - {[4- (4-chloro-phenyl-2-ram) -5- (4-cyclohexylpiperazine-1-ram) thiazole-2-ram] carbamoyl} pyridine-2-ram ) Carboxylic acid or salts, to increase levels of human platelet
IL245911A IL245911A0 (en) 2006-08-08 2016-05-29 Compositions and methods for increasing the level of blood platelets in humans

Country Status (8)

Country Link
US (2) US20080039475A1 (enExample)
EP (2) EP2056826B1 (enExample)
JP (3) JP2010500361A (enExample)
AU (2) AU2007284644B2 (enExample)
CA (1) CA2660283C (enExample)
ES (2) ES2452032T3 (enExample)
IL (4) IL196897A (enExample)
WO (1) WO2008021283A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1466912E (pt) * 2002-01-18 2013-06-28 Astellas Pharma Inc Derivado de 2-aciloaminotiazol ou seu sal
WO2011019990A1 (en) * 2009-08-14 2011-02-17 Eisai, Inc. Use of e5501 for stimulating platelet production
CN112022825B (zh) * 2020-08-24 2024-03-22 瑞阳制药股份有限公司 马来酸阿伐曲泊帕片剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5256675A (en) * 1989-08-07 1993-10-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
IE68593B1 (en) * 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
EP0620403B1 (de) * 1993-04-08 1996-12-04 ABB Management AG Misch- und Flammenstabilisierungseinrichtung in einer Brennkammer mit Vormischverbrennung
DE69629341T2 (de) * 1995-03-09 2004-06-09 Kyowa Hakko Kogyo Co., Ltd. Pyrrolocarbazolderivate
KR19990008109A (ko) * 1995-04-28 1999-01-25 나가사까 겐지로 1,4-이치환 피페리딘 유도체
CN1966520B (zh) * 1995-06-07 2012-07-11 葛兰素集团有限公司 结合血小板生成素受体的肽和化合物
US5963666A (en) * 1995-08-18 1999-10-05 International Business Machines Corporation Confusion matrix mediated word prediction
DE69626624T2 (de) * 1995-10-17 2003-11-27 Daiichi Suntory Pharma Co., Ltd. Medikamente gegen trhombocytopenie
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
AU762245B2 (en) * 1998-09-18 2003-06-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
EP1133291B1 (en) * 1998-11-17 2006-01-11 Smithkline Beecham Corporation Cyclic polyamines for treating thrombocytopenia
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
JPWO2002062775A1 (ja) * 2001-02-02 2004-06-10 山之内製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
WO2002062792A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
PT1466912E (pt) * 2002-01-18 2013-06-28 Astellas Pharma Inc Derivado de 2-aciloaminotiazol ou seu sal
CA2744893A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
WO2004029049A1 (ja) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 2-アシルアミノチアゾール誘導体の新規な塩
JP2006524688A (ja) * 2003-03-25 2006-11-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
JP4324791B2 (ja) * 2003-07-17 2009-09-02 アステラス製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
KR100776961B1 (ko) * 2003-08-12 2007-11-28 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 수용체 아고니스트 작용을 가지는 화합물
WO2007054783A2 (en) * 2005-11-08 2007-05-18 Astellas Pharma Inc. Compositions and methods for treating thrombocytopenia

Also Published As

Publication number Publication date
JP6258264B2 (ja) 2018-01-10
IL245911A0 (en) 2016-07-31
EP2056826A4 (en) 2009-09-09
EP2452674B1 (en) 2014-03-26
IL196897A0 (en) 2011-08-01
IL240323A0 (en) 2015-09-24
EP2452674A3 (en) 2012-05-30
ES2470333T3 (es) 2014-06-23
JP2013047257A (ja) 2013-03-07
IL240323A (en) 2016-05-31
EP2056826B1 (en) 2014-01-08
HK1170673A1 (en) 2013-03-08
EP2056826A2 (en) 2009-05-13
WO2008021283A2 (en) 2008-02-21
JP2015221806A (ja) 2015-12-10
WO2008021283A3 (en) 2008-12-11
US20110224226A1 (en) 2011-09-15
AU2007284644A1 (en) 2008-02-21
US20080039475A1 (en) 2008-02-14
AU2007284644B2 (en) 2011-09-01
CA2660283C (en) 2014-11-18
JP2010500361A (ja) 2010-01-07
ES2452032T3 (es) 2014-03-31
EP2452674A2 (en) 2012-05-16
IL240322A0 (en) 2015-09-24
AU2011253775B2 (en) 2014-02-13
CA2660283A1 (en) 2008-02-21
AU2011253775A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
WO2005039485A3 (en) Gsk-3 inhibitors and uses thereof
NO2020032I1 (no) Avatrombopag and pharmaceutically acceptable salts thereof, particularly avatrombopag maleate (1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl) thiazol-2-yl] carbamoyl} pyridin-2-yl) piperidine-4-carboxylic acid maleic acid salt
IL199152A (en) Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections
MX2009013272A (es) Formas amorfas estabilzadas de mesilato de imatinib.
TN2009000317A1 (en) Solid preparation comprising alogliptin and pioglitazone
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
CL2008000750A1 (es) Metodo para la administracion de una dosis semanal de 2-[6-(3-amino-piperidin-1-il)3-metil-2,4 dioxo-3,4 dihidro-2h-pirimidin-1-il metil]-4 fluoro-benzonitrilo; composicion farmaceutica de una forma de dosificacion individual de dicho compuesto; y su
IL189375A (en) Derivatives 1-Heterocyclicsulfonyl-3-Aminomethyl-5- (hetero-) aryl-1-h- Pyrol
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
IL194744A (en) Derivatives 1– (alkyl) –3– (amino-converted) –5– (converted) - s-triazole, a process for their preparation and pharmacological preparations containing them for the treatment of psychotic diseases
WO2009007411A3 (fr) Inhibition de la formation des ages
BR112012003462A2 (pt) "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
WO2010054167A3 (en) Limited proteolysis of cd2ap and progression of renal disease
NZ594556A (en) Carboxamide compounds and methods for using the same
WO2007116025A3 (en) Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
IL240323A (en) Preparations based on 1 - (3-chloro-5 - {[4- (4-chloro-phenyl-2-ram) -5- (4-cyclohexylpiperazine-1-ram) thiazole-2-ram] carbamoyl} pyridine-2-ram ) Carboxylic acid or salts, to increase levels of human platelet
IL201959A (en) Annals 2 - (1-Acetyl-Piperidine-4-Il) -4,2- Dihydro-Pyrazole-3-On
WO2011098799A3 (en) Respiratory disease treatment
MX337606B (es) Metodo y composiciones farmaceuticas para el tratamiento de la hiperglicemia postprandial de la diabetes tipo ii, a traves de la mucosa bucal.
WO2007104933A8 (en) Chemical compounds
WO2009136884A3 (en) Metformin-pioglitazone formulation with antihyperglycemic effects
IL187906A0 (en) Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
WO2007138233A3 (fr) Utilisation du zatosetron pour le traitement de la rosacee
WO2008016165A3 (en) Liquid preparation
PL2089030T3 (pl) Środek do zapobiegania lub leczenia uzależnienia od alkoholu lub uzależnienia od narkotyków

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed